^
    Back
    Association details:
    Biomarker:RAS wild-type + HER-2 positive
    Cancer:Colorectal Cancer
    Drug:Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Colorectal Cancer
    Title:

    Efficacy of pyrotinib with/without trastuzumab in treatment-refractory, HER2-positive metastatic colorectal cancer: result from a prospective observational study

    Published date:
    11/19/2023
    Excerpt:
    In this prospective observational study, patients with HER2 positive, RAS wild type mCRC...ORR were 50.0% and 25.0%, respectively….Pyrotinib with or without trastuzumab showed promising anti-tumor activity and acceptable toxicities in treatment-refractory, HER2-positive mCRC.
    DOI:
    https://doi.org/10.1016/j.clcc.2023.10.008